These “Tiny Bubbles” from Genprex (GNPX) Could Beat Cancer

These “Tiny Bubbles” from Genprex (GNPX) Could Beat Cancer

UPDATE 12-22-20 GNPX Now Up 40% For Our Members in 2 Days!

Good day everyone,

We are continuing our coverage of Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company involved in developing various approaches to treating cancer and diabetes.

Current price $3.56 per share
Outstanding shares (est.) 39.6M
Shares in Float (est.) 32.4M
Insider ownership 19%
Institutional ownership 17.5%

GNPX has a proprietary technology platform designed to deliver tumor suppressor genes to cancer cells, and autoimmune therapy currently focused on diabetes.

There is a plethora of small cap companies in the development stage working toward a cancer cure. That is a great thing because 606,520 Americans are projected to die of cancer in 2020. As many of our members know, we explore many of these companies and we intend to keep right on doing that.

Genprex has caught our eye, and we keep thinking about the technology they are developing. Their technology was developed by the M.D. Anderson Cancer Center, rated as one of the top two oncology centers in America for over a decade, both as to treatment and research.

GNPX has some things in common with our recent alert Vuzix. Both have been trending, GNPX has been trending all through the month of December. A look at the stock chart indicates GNPX shares have broken through their 50 DMA of $3.34 and their 200 DMA of $3.18 in a bullish manner. Their Simple Moving Averages, at all levels, are green.

Another thing GNPX has in common with VUZIX is remarkable patented technology that has experienced recent milestones and is in collaborations with some large enterprises (AstraZeneca, Merck). Both companies have similar share structures and significant levels of insider and institutional ownership.

GNPX has three products in development:

ONCOPREX® Nanoparticle Delivery System – This mRNA platform was originally developed through research between the University of Texas MD Anderson Cancer Center and the National Institutes of Health. Cancer-fighting genes are encapsulated in nanoscale hollow spheres or tiny bubbles called “nanoparticles,” which are then administered intravenously.

oncoprex image Genprex GNPX

REQORSA is the company’s lead product. REQORSA consists of the TUSC2 gene encapsulated in a positively charged nanoparticle (Oncoprex) made from lipid molecules with a positive electrical charge. REQORSA is injected intravenously and can specifically target cancer cells. The FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso for the treatment of non-small cell lung cancer.

GPX-002, has the potential to treat Type 1 and Type 2 diabetes, which together currently affect approximately 34.2 million people in the U.S., or 10.5 percent of the population.

Consider recent (December) developments at Genprex:

Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy

GNPX has completed the transfer of its manufacturing process for REQORSA™ from the cancer research institution where it was previously manufactured to experienced, commercial Contract Development and Manufacturing Organizations (CDMOs).

Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines Genprex’s lead drug candidate, REQORSA™ immunogene therapy with AstraZeneca PLC’s Tagrisso.

The transfer of manufacturing for REQORSA to a facility outside of a research institution is a major milestone for the company. It may mean that GNPX is ready to collaborate with more pharma companies beyond the upcoming clinical trials that combine REQORSA with Tagrisso® (AstraZeneca) and with Keytruda® (Merck & Co., Inc.)

2 Wall Street analysts have issued ratings and price targets in the last 12 months. Their average twelve-month price target is $5.00, predicting that the stock has a possible upside of 40.45%. Both analysts have a consensus rating of “Buy.”

GNPX shares have seen peaks this year ranging from $4.50 to $5.50 per share. The recent positive developments at the company may indicate it’s time to move beyond those 2020 peak levels.

Do your due diligence on GNPX and perhaps this advanced, cancer fighting technology they are developing will stick with you as well. Stay tuned, we want to talk to you more about GNPX “Tiny Bubbles” and more.

We will be back with more.

Stay tuned and stay informed,
The Traders News Group


Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s sister company (scs llc) has been compensated ten thousand dollars cash via bank wire by legends media llc for this week’s updated coverage of gnpx. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.